45 studies found for:    MLN9708
Show Display Options
Rank Status Study
1 Recruiting MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Condition: Advanced Cancers
Interventions: Drug: MLN9708;   Drug: Vorinostat
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: June 2014
Primary Completion: June 2021
2 Recruiting Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: SCRI Development Innovations, LLC;   Millennium Pharmaceuticals, Inc.
Study Start: August 2014
Primary Completion: June 2017
3 Recruiting MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Condition: Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: MLN9708
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Mehdi Hamadani;   Medical College of Wisconsin
Study Start: November 2014
Primary Completion: September 2021
4 Recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Nantes University Hospital
Study Start: October 2014
Primary Completion: January 2019
5 Not yet recruiting Phase I Study of the Combination of MLN9708 and Fulvestrant
Condition: Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: MLN9708
Phase: Phase 1
Sponsor: Dartmouth-Hitchcock Medical Center
Study Start: March 2015
Primary Completion: May 2017
6 Recruiting MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: December 2017
7 Recruiting Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: March 2014
Primary Completion: February 2017
8 Recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
Phase: Phase 1
Sponsor: Case Comprehensive Cancer Center
Study Start: May 2014
Primary Completion: July 2015
9 Recruiting Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Conditions: Multiple Myeloma;   Advanced Solid Tumors
Intervention: Drug: ixazomib (MLN9708)
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: September 2013
Primary Completion: August 2015
10 Recruiting A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Autologous Stem Cell Transplant
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: July 2014
Primary Completion: February 2018
11 Recruiting Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Condition: Lymphoma, T-Cell
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor: University of Michigan Cancer Center
Study Start: September 2014
Primary Completion: September 2018
12 Suspended Phase I Study of (Modified VXLD) Plus MLN9708 in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia;   Relapsed or Refractory Lymphoma
Interventions: Drug: MLN9708;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG asparaginase;   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Ehab L Atallah;   Medical College of Wisconsin
Study Start: October 2013
Primary Completion: December 2017
13 Recruiting Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Conditions: Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
Study Start: September 2014
Primary Completion: July 2016
14 Recruiting Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
Interventions: Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
Phase: Phase 1
Sponsor/Collaborators: Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
Study Start: December 2014
Primary Completion: October 2017
15 Active, not recruiting Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: May 2011
Primary Completion: December 2013
16 Withdrawn MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone
Phase: Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
Study Start: July 2012
Primary Completion: March 2014
17 Recruiting Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 3
Sponsor/Collaborators: PETHEMA Foundation;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
Study Start: November 2014
Primary Completion: September 2020
18 Withdrawn Ixazomib Citrate in Treating Patients With Untreated B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
Phase: Phase 2
Sponsor/Collaborators: University of Washington;   National Cancer Institute (NCI)
Study Start: May 2015
Primary Completion: November 2018
19 Recruiting Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
Conditions: Plasma Cell Myeloma;   Residual Disease
Interventions: Drug: Ixazomib Citrate;   Drug: Lenalidomide;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
Phase: Phase 2
Sponsor/Collaborators: University of Chicago;   National Cancer Institute (NCI)
Study Start: April 2015
Primary Completion: April 2019
20 Recruiting Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
Condition: Leukemia
Intervention: Drug: Ixazomib
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium: The Takeda Oncology Company
Study Start: March 2015
Primary Completion: March 2021

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years